Document Detail

Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
MedLine Citation:
PMID:  12591833     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: In unstable coronary artery disease short term treatment with low molecular weight heparin in addition to aspirin has been shown to be effective.
OBJECTIVE: To assess the cost effectiveness of extended treatment with dalteparin in patients managed with a non-invasive treatment strategy.
DESIGN: Prospective, randomised, multicentre study.
SETTING: 58 centres in Sweden, Denmark, and Norway, of which 16 were interventional.
PATIENTS: After at least five days' treatment with open label dalteparin, 2267 patients were randomised to continue double blind treatment with either subcutaneous dalteparin twice daily or placebo for three months. The patients' use of health service resources was recorded prospectively.
MAIN OUTCOME MEASURE: Death/myocardial infarction.
RESULTS: After one month into the double blind period there was a 47% relative reduction in death or myocardial infarction in the dalteparin group compared with the placebo group (p = 0.002). There was a non-significant mean cost difference, favouring the placebo group, of 849 Swedish crowns (SEK) per patient (equivalent to 58 pounds sterling). The incremental cost effectiveness ratio for giving dalteparin treatment for one month was SEK 30 300 (range -78 000 to 139 000) (2060 pounds sterling, range -5300 pounds sterling to pound 9400 pounds sterling) per avoided death or myocardial infarct. At three months, the decrease in death or myocardial infarction was not significant, precluding cost effectiveness analyses.
CONCLUSIONS: There is a marginal and non-significant increase in costs for one month of extended dalteparin treatment compared with placebo. Extended dalteparin treatment lowers the risk of death or myocardial infarction in patients with unstable coronary artery disease. While in many countries the resources for early intervention are limited, extended dalteparin treatment up to one month is a cost effective bridge to invasive intervention.
M Janzon; L-A Levin; E Swahn;
Related Documents :
9527073 - Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable...
8720743 - Pharmacological properties of hirudin and its derivatives. potential clinical advantage...
4092373 - The effects of nifedipine on the systemic and coronary vascular beds of the sheep: a po...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  89     ISSN:  1468-201X     ISO Abbreviation:  Heart     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-02-19     Completed Date:  2003-03-14     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  England    
Other Details:
Languages:  eng     Pagination:  287-92     Citation Subset:  AIM; IM    
Institution of Medicine and Care, Linköping University, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anticoagulants / economics*,  therapeutic use
Coronary Artery Disease / drug therapy,  economics*
Cost-Benefit Analysis
Dalteparin / economics*,  therapeutic use
Follow-Up Studies
Hospitalization / economics
Middle Aged
Prospective Studies
Sensitivity and Specificity
Reg. No./Substance:
0/Anticoagulants; 0/Dalteparin
Comment In:
Heart. 2003 Mar;89(3):249-50   [PMID:  12591818 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for ...
Next Document:  Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to c...